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Abstract:  A portable, depth-sensitive clinical spectroscopy device for 
noninvasive early diagnosis of oral cancer is described. We carried out a 
pilot study to evaluate the ability of the device to identify oral neoplasia 
using a previously developed diagnostic algorithm. A total of 79 oral sites in 
33 subjects, including 28 patients with oral lesions and 5 healthy volunteers, 
were measured and analyzed. Measurements of 54 nonkeratinized oral sites 
yielded an area under the receiver operating characteristic curve of 0.90. 
Measurements of 25 keratinized oral sites yielded an area under the receiver 
operating characteristic curve of 0.83. 
©2010 Optical Society of America 
OCIS codes:  (170.6510) Spectroscopy, tissue diagnostics; (170.3890) Medical optics 
instrumentation. 
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Approximately 390,000 new cases of oral cancer and oropharyngeal cancer occur worldwide 
each year, of which about two-thirds are in developing nations [1]. In the United States an 
estimated 161,000 men and 88,000 women are currently living with a diagnosis of cancer of 
the oral cavity or pharynx, and the overall five-year survival rate for patients with the disease 
is 61% [2]. Major advances have been made in basic treatment methods including surgery, 
radiotherapy and chemotherapy [3]. However, early diagnosis remains critically important. 
The five-year survival rate in the United States is 83% for oral cancer patients diagnosed 
when the cancer is localized, 55% when it has spread to regional lymph nodes, and 32% when 
it has metastasized; but only one-third of patients are diagnosed at the early, localized stage 
[2]. 
Risk factors for oral and oropharyngeal cancer include the use of tobacco, alcohol, betel 
quid, areca nut, and paan, increased age, immunological compromise, unhealthy diet, and 
infection with the human papilloma virus [4]. Opportunistic screening for oral cancer typically 
occurs through visual and tactile examination of the oral cavity by a dental or medical 
professional, or other health care worker during a general examination. An expert panel of the 
American Dental Association Council recommends that clinicians remain alert for signs of 
potentially malignant lesions while performing routine dental examinations, especially in 
patients who are at high risk due to tobacco or alcohol use; however, the panel cautions that 
there is not yet sufficient evidence to determine whether routine screening of asymptomatic 
patients actually reduces mortality due to oral cancer [5]. Furthermore, while awareness of the 
importance of oral cancer screening is increasing, surveys indicate that a significant fraction 
of dentists and physicians do not consider themselves adequately trained to perform screening 
procedures [6–8]. Low-cost, robust diagnostic aids that can be implemented in low-resource 
settings are needed, as well as further studies on the predictive power of population-based oral 
cancer screening [9]. 
Adjunctive techniques for early detection and diagnosis of oral cancer include brush 
biopsy, toluidine blue staining, chemiluminescence, optical imaging, and optical spectroscopy 
[10]. While some of these diagnostic aids show promise, none has yet been definitively 
proven to perform better than conventional visual examination [11,12]. The accepted method 
for diagnosis of oral cancer and potentially malignant lesions remains clinical examination 
and histopathological evaluation of biopsied tissue [5]. 
Optical spectroscopy is a noninvasive diagnostic method that has been investigated in 
many forms including fluorescence spectroscopy, elastic or diffuse scattering spectroscopy, 
and Raman spectroscopy [13]. Spectroscopic measurements can detect  biochemical and 
architectural alterations in tissue that are related to the progression of precancer and therefore 
provide diagnostic information [13–15]. These alterations may include changes in the 
concentrations of native fluorophores such as collagen, elastin, keratin, nicotinamide adenine 
dinucleotide (NADH), and flavin adenine dinucleotide (FAD); changes in hemoglobin 
concentration and oxygenation; increasing epithelial thickness; and increasing nuclear size 
and nuclear/cytoplasmic ratio [16–18]. 
Investigations of autofluorescence spectroscopy of oral lesions in vivo  have identified 
differences among the emission spectra of normal, premalignant and malignant tissues at 
excitation wavelengths in the ultraviolet and visible region [19–22]. Considerable success has 
been reported in distinguishing lesions from healthy oral mucosa, but the spectral variations 
among different anatomic sites within the oral cavity and the problem of discriminating 
benign lesions from precancerous/cancerous lesions continue to  pose challenges [23,24]. 
Recent investigations reflect these complexities, including measurement techniques that target 
localized, superficial tissue regions where early premalignant changes are believed to occur 
[25,26]; algorithms that are explicitly based on specific anatomic sites within the oral cavity 
[27]; and multi-class algorithms that are designed to classify tissue into a range of diagnostic 
categories [28]. 
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regions in tissue [29] and incorporated it into a clinical spectroscopy device [30]. We carried 
out a clinical study of depth-sensitive optical spectroscopy [31] to identify the most 
diagnostically useful illumination wavelengths and to develop an algorithm for diagnostic 
classification of nonkeratinized oral tissue. While these results showed good sensitivity and 
specificity, the device was not easily portable and was therefore not well suited for 
community-based health care settings. Here we describe a compact, portable version of the 
depth-sensitive optical spectroscopy device that is designed to measure only the most 
diagnostically useful parameters. The portable device was evaluated through measurements of 
79 oral sites in 33 subjects, including 28 patients with oral lesions and 5 healthy volunteers. 
2. Methods 
2.1 Instrumentation 
The portable depth-sensitive spectroscopy device is shown in Fig. 1. It is 36 cm x 20 cm x 25 
cm in size and weighs 6.3 kg. Light-emitting diodes (LEDs) are used for illumination. Two 
LEDs are used for fluorescence excitation: part #NCSU034A (Nichia Corporation, 
Tokushima, Japan, 310 mW at 500 mA, peak wavelength 385 nm). A 385-nm bandpass filter 
with a spectral full width of 11 nm (Semrock, Inc., Rochester, New York) is placed in each 
fluorescence excitation pathway. Two LEDs are used for reflectance illumination: Vio High 
Power White LED part #GE-VHD-1A-3C7 (GE Lumination, East Cleveland, Ohio, 180 
lumens at 350 mA). A 320-nm longpass filter (Edmund Optics Inc., Barrington, New Jersey) 
is placed in each reflectance illumination pathway. Light is delivered and collected via a ball-
lens coupled fiber optic probe that is placed in contact with the tissue. The probe contains two 
depth channels: a shallow depth channel designed to target the epithelium (a depth region 
from approximately 0 μm – 400 μm), and a medium depth channel designed to target the 
epithelium and shallow stroma (a depth region from approximately 0 μm – 900 μm). The 
probe is identical to a previously described depth-sensitive probe [30] except that the 
illumination and collection fibers for the two deep channels have been omitted in the current 
probe. Collected light is delivered through a 405-nm longpass filter (Chroma Technology 
Corp., Rockingham, Vermont) to a miniature spectrometer (USB2000 + , Ocean Optics, Inc., 
Dunedin, Florida). Light sources and optical filters are dedicated to their respective 
measurement channels and there are no moving parts. Automated data acquisition, real-time 
processing and diagnostic classification are controlled by a laptop computer using LabVIEW 
software (National Instruments Corporation, Austin, Texas) for instrumentation control and 
MATLAB software (The MathWorks, Inc., Natick, Massachusetts) for data analysis. The total 
cost of components, including the depth-sensitive probe and the laptop computer, is less than 
10,000 USD. 
 
Fig. 1. Photograph and diagram of the portable depth-sensitive optical spectroscopy device. 
Fluorescence spectra and diffuse reflectance spectra are collected through each of the two 
depth channels. Fluorescence spectra are collected using 385 nm excitation (11 nm full width 
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device collects four spectra per measurement: fluorescence measured in the medium depth 
channel (FM), fluorescence measured in the shallow depth channel (FS), reflectance measured 
in the medium depth channel (RM), and reflectance measured in the shallow depth channel 
(RS). Optical power is adjusted independently in each channel such that the detected signal 
level is in an optimal range (high signal to noise ratio, but not near saturation). The optical 
power delivered to the tissue in each case is 155 μW (FM), 155 μW (FS), 3.5 μW (RM) and 
5.5 μW (RS). A background spectrum is also collected with no illumination. The use of a 
limited set of depth channels and illumination wavelengths enables compact design and rapid 
data acquisition, while still allowing depth selectivity and measurement of key features. Each 
spectrum is collected with an integration time of 500 ms and the total time required for a 
complete measurement is 5 seconds. 
2.2 Human subjects 
The study was conducted at the University of Texas M. D. Anderson Cancer Center 
(MDACC). The study was approved by the Institutional Review Boards at MDACC and Rice 
University. Patients with lesions of the oral mucosa and healthy volunteers 18 years or older 
were recruited to participate. Written informed consent was obtained from all subjects. 
2.3 Measurement procedure 
Spectroscopic measurements of patients were performed in the operating room at MDACC 
immediately prior to surgery (26 patients) or in the Head & Neck clinic (2 patients). The oral 
cavity was first inspected visually. Several sites in each subject were selected for 
spectroscopic measurement, including at least one oral lesion and at least one contralateral site 
with a normal clinical appearance. The clinical appearance of each measured site, as judged 
by an expert observer, was recorded and categorized as normal, abnormal low risk for 
neoplasia, abnormal high risk for neoplasia, or cancer. The probe was placed gently in contact 
with the site and held in place by the clinician for two successive measurements. 
Measurements were performed in a darkened room to minimize the effects of ambient light. 
Upon completion of the optical measurements 4-mm punch biopsies were collected from 
one abnormal-appearing measurement site and one normal-appearing contralateral 
measurement site. Specimens were placed in fixative  and submitted for histopathologic 
evaluation. Histopathology diagnoses were categorized as normal/benign, mild dysplasia, 
moderate/severe dysplasia, or cancer using standard diagnostic criteria [32,33]. 
Normal/benign was defined as normal, hyperkeratosis,  hyperplasia, and/or inflammation 
without dysplasia or with only focal mild dysplasia; there were no benign tumors in the study. 
In this group of 28 patients, measurement sites without a corresponding biopsy to serve as the 
gold standard were excluded from the analysis. 
Measurements of five healthy volunteers were performed in an examination room at 
MDACC. In healthy volunteers biopsies were not performed but the clinical appearance of 
measured sites was noted. 
Optical calibration standards were measured daily before or after patient measurements. 
Calibration standards included two positive fluorescence standards (Rhodamine B in ethylene 
glycol, 2 mg/L and 8 g/L); two negative fluorescence standards (frosted surface of a quartz 
cuvette and deionized ultrafiltered water); and a positive reflectance standard (Teflon). The 
spectrum of a calibrated tungsten halogen light source (Ocean Optics, Inc.) was measured and 
used to correct for nonuniform spectral variations in the throughput of the detection system. 
2.4 Data analysis 
Data processing and analysis consisted of the following steps: (1) processing of spectroscopic 
data to yield calibrated reflectance and fluorescence spectra, (2) extraction of quantitative 
optical features required for the classification algorithm, (3) application of the classification 
algorithm to calculate the posterior probability of disease, and (4) application of a threshold 
value to generate a diagnostic prediction. The prior probability of disease was set to 0.50. 
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subtraction, correction for illumination energy, correction for system throughput, and (for 
reflectance data) calculation of the ratio of tissue reflectance to the reflectance of a white 
Teflon standard. FM, FS, and RS spectra measured with the portable device were used 
directly as processed. A multiplicative correction factor was applied to the processed RM 
spectra to account for inter-instrument differences between the portable device and the 
instrument that was originally used to develop the algorithm; these differences were 
associated with probe-to-probe variations in stray light reflected from the ball lens surfaces 
within the probe tip. This inter-instrument correction factor was developed from healthy 
volunteer data and standards data collected prior to the clinical study reported here. 
The classification algorithm used in this study has been previously described [31]. It is a 
two-class linear discriminant analysis-based classifier that was developed for nonkeratinized 
oral tissue in a previous clinical study. The algorithm generates a posterior probability and a 
diagnostic prediction based on features of the autofluorescence and reflectance spectra. The 
algorithm uses six spectral features as input values for classification: (1) 472 nm fluorescence 
emission intensity at 385 nm excitation, medium depth channel; (2) ratio of reflectance 
intensity at 650 nm to reflectance intensity at 500 nm, medium depth channel; (3) ratio of 
reflectance intensity at 500 nm to reflectance intensity at 420 nm, medium depth channel; (4) 
reflectance intensity at 500 nm, medium depth channel; (5) ratio of 478 nm fluorescence 
emission intensity to 458 nm fluorescence emission intensity at 385 nm excitation, medium 
depth channel; and (6) reflectance intensity at 420 nm, shallow depth channel. 
Nonkeratinized oral sites in the current data set were classified using the original 
classification algorithm and threshold value for posterior probability (0.55) without 
modification. Keratinized oral sites in the current data set were classified using the same 
classification algorithm, but for keratinized tissue the threshold value was optimized 
retrospectively to 0.94 to maximize the sum of the sensitivity and specificity. Processing and 
classification were done in real time such that the fully processed spectra, the posterior 
probability value, and the diagnostic prediction were available immediately after the 
completion of the measurement. The higher posterior probability value resulting from two 
measurements at a given site was used as the posterior probability value for that site. 
For sites in patients, the histopathology result from the biopsy taken at the measurement 
site was used as the gold standard. Histopathology diagnoses of normal/benign or mild 
dysplasia were considered non-neoplastic; diagnoses of moderate/severe dysplasia or cancer 
were considered neoplastic. For healthy volunteers, expert clinical impression was used as the 
gold standard since no biopsies were collected. 
Sensitivity, specificity, positive predictive value, and negative predictive value were 
calculated on a per-site basis with respect to the gold standard. Confidence intervals were 
calculated using the Clopper-Pearson method. 
3. Results 
During the  8-month period from November 2009 to June 2010, 264 measurements were 
collected from 135 sites in 29 patients, and 48 measurements were collected from 24 sites in 5 
healthy volunteers. All measurements passed a quality control check. Histopathology results 
from a corresponding biopsy were available for 110 measurements in 55 sites in 28 patients; 
all of these measurements were included in the analysis. All measurements in healthy 
volunteers were included in the analysis. The final data set consisted of 158 measurements 
from 79 sites in 33 subjects, as shown in Table 1. 
Of the 79 sites in the data set, 54 sites were at anatomic locations categorized here as 
nonkeratinized, including lateral tongue (24), buccal mucosa (13), floor of mouth (9), and 
ventral tongue (8). There were 25 sites at anatomic locations categorized as keratinized, 
including gingiva (15), hard palate (7), mandible (2) and dorsal tongue (1). 
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      Patients  Healthy Volunteers  Total 
Data set  Subjects  28  5  33 
   Sites  55  24  79 
   Measurements  110  48  158 
  
Subset:  Subjects represented
a  21  5  26 
Nonkeratinized tissue  Sites  40  14  54 
   Measurements  80  28  108 
  
Subset:  Subjects represented
a  9  5  14 
Keratinized tissue  Sites  15  10  25 
   Measurements  30  20  50 
aSome subjects are represented in both the nonkeratinized subset and the keratinized subset. 
 
Table 2  shows the expert clinical impression and the corresponding histopathologic 
diagnosis for sites in patients. Of the 55 sites in patients, 29 were non-neoplastic 
(normal/benign or mild dysplasia) and 26 were neoplastic (moderate/severe dysplasia or 
cancer) according to histopathology. The 24 sites in healthy volunteers were all considered 
non-neoplastic based on clinical impression, including one site described as abnormal low risk 
due to inflammation. 
Table 2. Clinical Impression vs. Histopathology for Sites in Patients 
Histopathology  Expert Clinical Diagnosis 
Total Sites  Diagnosis  Normal  Abnormal Low Risk  Abnormal High Risk  Cancer 
Normal/benign  23  1  0  0  24 
Mild dysplasia  2  0  2  1  5 
Moderate/severe dysplasia  0  0  3  2  5 
Cancer  0  1  1  19  21 
  
Total sites  25  2  6  22  55 
 
Figure 2 shows average spectra collected from nonkeratinized sites (108 spectra from 54 
sites) broken down by diagnosis.  Plots are shown for fluorescence medium depth, 
fluorescence shallow depth, reflectance medium depth, and reflectance shallow depth 
configurations. These plots suggest that for nonkeratinized tissue, the spectral characteristics 
of neoplastic sites (moderate/severe dysplasia or cancer, shown in red) are distinct from those 
of non-neoplastic sites (normal or mild dysplasia, shown in blue). The most striking 
characteristic of the spectra shown in Fig. 2  is the substantial decrease in blue-green 
autofluorescence of neoplastic tissue compared to non-neoplastic tissue, observed in both the 
medium and shallow depth channels. A decrease in the intensity of the reflectance spectra 
from neoplastic tissue is also observed in both the medium and shallow depth channels. 
In addition to intensity differences, small shape differences may be noted in the average 
spectra. The average reflectance spectra from cancer sites display a slightly deeper valley at 
420 nm relative to 500 nm than the average reflectance spectra from normal sites. The average 
fluorescence spectra from neoplastic sites display a small peak at 635 nm, associated with 
porphyrin fluorescence, that is not present in the spectra from non-neoplastic sites. 
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Fig. 2. Average spectra of nonkeratinized oral sites.  Nm: Normal. MiDy: Mild Dysplasia. 
MoSvDy: Moderate/Severe Dysplasia. Ca: Cancer. Number in parentheses indicates number of 
spectra represented in the average. Error bars, shown only for categories with >10 spectra, 
indicate standard error of the mean. 
 
Fig. 3. Average spectra of keratinized oral sites. Nm: Normal. MiDy: Mild Dysplasia. 
MoSvDy: Moderate/Severe Dysplasia. Ca: Cancer. Number in parentheses indicates number of 
spectra represented in the average. Error bars, shown only for categories with >10 spectra, 
indicate standard error of the mean. 
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in the same format. Greater variability is observed in the fluorescence spectra for keratinized 
tissue, indicated by the larger error bars in Fig. 3 compared to Fig. 2. Despite this greater 
variability, the same overall trends of reduced fluorescence intensity and reduced reflectance 
intensity are observed in cancer sites relative to normal sites. 
Table 3 summarizes the sensitivity, specificity, positive predictive value, and negative 
predictive value obtained in this study using the portable device. Figure 4  shows the 
corresponding receiver operating characteristic (ROC) curves. For nonkeratinized sites the 
area under the ROC curve was 0.90. At the point indicated on the ROC curve, corresponding 
to a preestablished threshold value, sensitivity was 84% (16/19) and specificity was 91% 
(32/35). The preestablished threshold was very close to the optimal value (Q-point) on the 
ROC curve for nonkeratinized sites. For keratinized sites the area under the ROC curve was 
0.83. At the point indicated on the ROC curve, corresponding to a retrospectively established 
threshold, sensitivity was 86% (6/7) and specificity was 83% (15/18). 
Of the 79 sites in the data set, 6 sites were misclassified as false positive and 4 sites were 
misclassified as false negative. Sites misclassified as false positive included tongue (2), floor 
of mouth (1), and gingiva (3). Three of the false positive sites were in patients, including two 
normal sites and one site with mild dysplasia according to histopathology; the other three sites 
were in healthy volunteers. Sites misclassified as false negative included buccal mucosa (1), 
tongue (1), floor of mouth (1), and gingiva (1). All of the false negative sites were cancer 
according to histopathology. 
The relationship between inflammation and diagnostic performance was examined. The 
presence or absence of inflammation at each measurement site was determined by 
histopathology (for sites in patients) or by clinical impression (for sites in healthy volunteers). 
Chronic and/or acute inflammation was present in 28% of the non-neoplastic sites and in 96% 
of the neoplastic sites in the study. Of the 6 non-neoplastic sites misclassified as false positive, 
3 sites (50%) had inflammation present. Of the 4 neoplastic sites misclassified as false 
negative, 4 sites (100%) had inflammation present. 
Table 3. Diagnostic Performance of the Portable Spectroscopy Device
a 
   Nonkeratinized Tissue  Keratinized Tissue 
Sensitivity  0.84 (0.60, 0.97)  0.86 (0.42, 0.996) 
Specificity  0.91 (0.77, 0.98)  0.83 (0.59, 0.96) 
Positive predictive value  0.84 (0.60, 0.97)  0.67 (0.30, 0.93) 
Negative predictive value  0.91 (0.77, 0.98)   0.94 (0.70, 0.998) 
a95% confidence intervals are shown in parentheses. 
 
Fig. 4. Receiver operating characteristic curves for (a) nonkeratinized sites and (b) keratinized 
sites. Arrow in (a) corresponds to a preestablished threshold; arrow in (b) corresponds to a 
retrospectively established threshold. Se: sensitivity. Sp: specificity. AUC: Area under curve. 
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Many groups have reported the development of methods for diagnostic classification of oral 
tissue based on autofluorescence and/or diffuse reflectance spectroscopy. Müller et al reported 
a sensitivity of 96% and a specificity of 96% for distinguishing cancerous/dysplastic tissue 
from normal tissue in a study of 23 subjects [14]. De Veld et al obtained areas under the ROC 
curve up to 0.90 for distinguishing lesions from healthy oral mucosa in a study of 225 subjects 
[15]. McGee et al reported areas under the ROC curve of 0.81-0.97 for distinguishing lesions 
from healthy mucosa, and 0.60-0.75 for distinguishing benign from dysplastic/malignant 
lesions, in a study of 71 patients [27]. 
Results are often reported within the data set used to develop the diagnostic classification 
technique, with or without cross-validation. Studies that apply a previously developed 
diagnostic algorithm to an independent validation set are less frequent. In a recent study of 
124 subjects we developed a diagnostic algorithm for nonkeratinized tissue and applied it to 
both the training set and an independent validation set [31]. We obtained a sensitivity and 
specificity of 94% and 90%, respectively, in the training set and 82% and 87%, respectively, 
in the validation set. Here we report the successful application of that same algorithm to a 
validation data set that is not only independent, but was in fact collected using a different 
instrument – a much smaller, portable version of the device. 
Of the six spectral features used by the algorithm, spectral feature #1 captures the decrease 
in blue-green autofluorescence intensity, believed to be primarily due to the breakdown of 
collagen crosslinks in the shallow stroma, that occurs in neoplastic tissue. Spectral feature #2 
characterizes changes in the slope of the reflectance spectrum that occur as increased nuclear 
size and crowding lead to an increase in scattering in the epithelium relative to the shallow 
stroma, and as angiogenesis leads to increased hemoglobin absorption in the stroma. Spectral 
features #3, #4, and #6 are associated with changes in hemoglobin absorption due to the 
growth of new blood vessels. Spectral feature #5 identifies changes in shape of the 
fluorescence spectrum due to alterations in the contributions from NADH, FAD and keratin in 
the epithelium, and a reduced contribution from collagen in the stroma. The algorithm does 
not use porphyrin fluorescence in the 635-nm wavelength region as a diagnostic feature; this 
fluorescence is frequently observed in neoplastic tissue but in the training set it was not found 
to be a sufficiently reliable diagnostic predictor. The relationship between biological 
alterations and spectral characteristics is explored in detail elsewhere [34]. 
The current study confirms previous results indicating spectral differences between 
healthy and diseased tissue. Neoplasia appears to be associated with a decrease in blue-green 
fluorescence intensity. The classification algorithm uses this change in fluorescence intensity, 
measured in the medium depth channel (spectral feature #1), as the primary feature for 
diagnostic prediction. Sites with strong fluorescence intensity in the medium depth channel 
are usually classified as negative by the algorithm, while sites with loss of fluorescence in the 
medium depth channel are typically classified as positive. Alterations in the shape and 
intensity of the reflectance spectra (spectral features #2, #3, #4, #6) and in the shape of the 
fluorescence peak (spectral feature #5) also affect the diagnostic prediction. 
As in previous studies, spectral differences were also observed between nonkeratinized 
and keratinized oral sites. Keratinized sites in the oral cavity, such as the gingiva and hard 
palate, are characterized by a protective keratin layer in the superficial epithelium and dense 
connective tissue in the stroma. Like other oral sites, neoplastic keratinized sites typically 
display a decrease in blue-green autofluorescence due to the breakdown of collagen crosslinks 
and increased hemoglobin absorption due to angiogenesis. However, the superficial layer of 
keratin is variable in thickness and can be highly scattering, providing a variable amount of 
shielding of collagen and other subsurface fluorophores from optical interrogation. The 
keratin layer is also itself fluorescent, with a blue fluorescence peak under ultraviolet 
illumination. In this study greater variability in fluorescence intensity was observed in 
keratinized tissue than in nonkeratinized tissue, and keratinized sites proved more difficult to 
classify. 
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volunteers typically had moderate to low fluorescence intensity, while histologically normal 
sites in patients tended to have substantially higher fluorescence intensity (Fig. 5b). This 
makes classification of keratinized sites in a mixed population of patients and healthy 
volunteers more challenging. One contributing factor to this difference between healthy 
volunteers and patients may have been that gingival sites in healthy volunteers were typically 
located adjacent to teeth, while teeth were often missing at the corresponding sites in patients. 
The difference was much less evident in nonkeratinized tissue (Fig. 5a). Despite these issues, 
the diagnostic algorithm proved to be sufficiently robust for use with both nonkeratinized and 
keratinized tissue. 
It is believed that the presence of inflammation can be a potential source of false positive 
results for diagnostic methods based on tissue autofluorescence [35]. The design of the depth-
sensitive probe is intended to minimize this effect by interrogating the epithelium and 
minimizing the signal from the stroma. In this study three of the six false positive non-
neoplastic sites (50%) were found to have inflammation present. This percentage was higher 
than the fraction of all non-neoplastic sites which had inflammation present (28%). Based on 
this very small sample of sites, inflammation may have been a contributing factor but not the 
dominant factor in the false positive results obtained in this study. 
 
Fig. 5. Average fluorescence spectra of normal oral sites, measured using the medium depth 
channel, in (a) nonkeratinized tissue and (b) keratinized tissue. All Nm: All normal sites. Nm in 
Pts: Normal sites in patients only. Nm in H Vols: Normal sites in healthy volunteers only. 
Number in parentheses indicates number of spectra represented in the average. 
The portable spectroscopy device has proven to be well suited for clinical use due to its 
compact size and its rapid measurement capability. The device is rugged and can be easily 
transported between clinical sites without the need for optical realignment. Measurements are 
performed in a darkened room; however, the system performs well even in the presence of a 
low level of ambient light, which is useful in many clinical situations. We typically perform 
two successive 5-second measurements at each site; by verifying that the two sets of spectra 
are consistent, the operator can ensure that no patient movement or probe slippage occurred 
during the measurement. 
In summary, the diagnostic performance of a portable depth-sensitive spectroscopy device 
was evaluated in a clinical study involving 33 subjects. A previously developed classification 
algorithm was implemented to classify measured sites. Sensitivity and specificity were 84% 
and 91%, respectively, for nonkeratinized sites using a preestablished threshold. Sensitivity 
and specificity were 86% and 83%, respectively, for keratinized sites using a retrospectively 
established threshold. The development of portable clinical instrumentation and the 
implementation of algorithms for real-time diagnostic prediction should facilitate the 
translation of optical spectroscopy to community and low-resource settings where it can be 
used to aid in early diagnosis of oral cancer. 
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